EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quantifying the Financial Return on Investment of Risk-Based Quality Management Implementation in Clinical Development

Abigail Dirks iD, Sylviane de Viron, Kenneth McFarlane, Kenneth A Getz

Therapeutic Innovation & Regulatory Science · 2026

DOI: 10.1007/s43441-026-01002-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2026. Verfasst von Abigail Dirks und 3 weiteren Autor:innen. Beteiligte Einrichtung: Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, MA, USA. Abigail.Dirks@tufts.edu. Hauptthemen laut MEDLINE: Drug Development, Risk Management. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CluePoints.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite widespread receptivity to risk-based quality management (RBQM) principles, adoption has been limited as drug development stakeholders have lacked quantitative evidence demonstrating return on investment (ROI).

Methods

Two assessments were conducted to estimate the ROI of RBQM. (1) Clinical trial level ROI was derived by analyzing monitoring cost efficiencies and clinical phase duration reductions under a 10% source data verification (SDV) scenario. (2) Program-level ROI was derived using an expected net present value (eNPV) modeling approach. Both analyses included data based on actual RBQM use in 18 recently completed oncology trials, as well as published and proprietary industry benchmarks.

Results

RBQM use was associated with reductions of 8–19% in clinical phase durations and monitoring cost reductions of up to 18% under a 10% SDV scenario. Total clinical trial ROIs ranged from $3.2 million (phase 1) to $18.9 million (phase 3), corresponding to ROI multiples of 6× to 23×. Program-level eNPV gains ranged from $3.8 million in phase 1 to $13.8 million in phase 3 corresponding to ROI multiples of 4× to 14×.

Conclusions

The ROI demonstrated at the individual clinical trial level and at the development program level provides a compelling business case for adopting RBQM particularly given alignment with ICH E6 R3 guidelines encouraging risk-based approaches supporting clinical trial planning and execution. Study findings indicate that RBQM-supported oversight not only improves data quality and risk detection but also represents a strategic investment that can help optimize resource allocation, increase development efficiency and speed, and enhance portfolio productivity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentRisk ManagementHumansClinical Trials as TopicInvestmentsCost-Benefit Analysis

Stichwörter der Autor:innen

Centralized monitoringClinical trial efficiencyExpected net present valueICH E6(R3)Oncology drug developmentQuality by designReturn on investmentRisk-based quality managementSource data verification

Autor:innen und Institutionen

  • Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, MA, USA. Abigail.Dirks@tufts.edu.
  • Clue Points S.A, Louvain-la-Neuve, Belgium.
  • CluePoints Inc, King of Prussia, PA, USA.
  • Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, MA, USA.

ORCID-Profile: Abigail Dirks

Förderung

  • CluePoints

Zitieren

APA

Dirks, A., de Viron, S., McFarlane, K., & Getz, K. A. (2026). Quantifying the Financial Return on Investment of Risk-Based Quality Management Implementation in Clinical Development. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-026-01002-1

Vancouver

Dirks A, de Viron S, McFarlane K, Getz KA. Quantifying the Financial Return on Investment of Risk-Based Quality Management Implementation in Clinical Development. Therapeutic Innovation & Regulatory Science. 2026. doi:10.1007/s43441-026-01002-1

BibTeX
@article{Dirks2026,
  author = {Dirks, Abigail and de Viron, Sylviane and McFarlane, Kenneth and Getz, Kenneth A},
  title = {Quantifying the Financial Return on Investment of Risk-Based Quality Management Implementation in Clinical Development},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2026},
  doi = {10.1007/s43441-026-01002-1}
}
Kostenlos starten →